PerkinElmer Announces Innovations to Strengthen Drug Discovery Product Portfolio
Product News Apr 08, 2008
PerkinElmer, Inc. has announced the release of eight AlphaLISA™ immunoassay kits in conjunction with the Society for Biomolecular Sciences’ (SBS) 14th Annual Conference and Exhibition. These latest innovations include research reagents and assays for investigating HIV, cancer, central nervous system disorders, cardiovascular disorders, and diabetes(a).
AlphaLISA is a line of sensitive “No-Wash” immunoassay reagents offering a wide dynamic range and easy automation for analysis of biomarkers and other analytes. The technology allows researchers to replace multi-step, cumbersome ELISAs with a high throughput screening (HTS) platform, significantly reducing the time, labor and materials necessary for processing complex samples.
“At PerkinElmer, we are committed to providing our customers with the technologies and innovations they need to further push the boundaries of research taking place in today’s laboratories,” said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer, Inc. “The release of these eight new AlphaLISA assay kits will not only provide researchers with the latest tools they need to produce more accurate results across a wider range of diseases, but also expand and strengthen our line of drug discovery products in new and existing markets.”